Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Dr Reddy's shares soar 3.54% after Alvotech partnership for Keytruda biosimilar, enhancing global reach in cancer ...

Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar ...

Dr. Reddys shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture ...